Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Toripalimab · Loqtorzi, JS-001

Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Coherus Biosciences

Approved FDA, Oct 2023

CHRS Developer

5 Registered trials

What is Toripalimab?

Toripalimab is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of anti-tumor immunity. It is studied in head and neck squamous cell carcinomas, sarcomas, and other solid tumors, including nasopharyngeal carcinoma, and is also studied in combination with STC-15.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Loqtorzi, JS-001, TAB-001, CHS-007, STC-15, LOQTORZI
Drug type: Monoclonal antibody
Targets: Programmed cell death protein 1 (PD-1) (PDCD1), Programmed death-ligand 1 (PD-L1) (CD274) (binding partner it blocks), Programmed death-ligand 2 (PD-L2) (PDCD1LG2) (binding partner it blocks)
Mechanism: Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways: PD-1 signaling pathway, T-cell activation and proliferation, anti-tumor immune response
Therapy area: Oncology
Developer: Coherus Biosciences Inc (CHRS)
FDA status: Approved as Loqtorzi (October 27, 2023), BLA761240 · FDA label
UNII: 8JXN261VVA

✅ FDA-approved uses

Nasopharyngeal carcinoma

From the indications section of the FDA label (version of Jul 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06457503	Phase 4	Nasopharyngeal Cancer Recurrent	Recruiting	CHRS
NCT07214987	Phase 2	Squamous Cell Carcinoma	Recruiting	CHRS
NCT07209189	Phase 2	Head and Neck Cancer	Recruiting	CHRS
NCT06975293	Phase 1/2	Solid Tumor	Recruiting	CHRS
NCT05757492	Phase 1	Advanced Solid Tumor	Terminated	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dedifferentiated LiposarcomaHead and Neck CancerHead and Neck Cancer Squamous Cell CarcinomaHPV (Human Papillomavirus)-Associated CarcinomaHPV 16 Positive Oropharyngeal Tumors (OPC)Laryngeal CancerLeiomyosarcomaNasopharyngeal Cancer RecurrentOral Cavity CancerOropharyngeal CancerSarcomaSinonasal Squamous Cell CarcinomaSkull Base TumorsSolid Tumor

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2 Ivonescimab Phase 3

More from Coherus Biosciences

Casdozokitug Phase 2 CHS-0214 Phase 3 CHS-1000 Phase 1 Perenostobart Phase 2 Tagmokitug Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CHRS page.

Follow CHRS, the company behind Toripalimab

See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CHRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z